PMID- 29355544
OWN - NLM
STAT- MEDLINE
DCOM- 20180226
LR  - 20220408
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 196
DP  - 2018 Mar 1
TI  - Quercetin suppresses breast cancer stem cells (CD44(+)/CD24(-)) by inhibiting the 
      PI3K/Akt/mTOR-signaling pathway.
PG  - 56-62
LID - S0024-3205(18)30020-1 [pii]
LID - 10.1016/j.lfs.2018.01.014 [doi]
AB  - AIMS: Cancer stem cells (CSCs) are considered the prime source of cancer 
      recurrence, metastasis, and progression and represent important targets for 
      developing novel anticancer agents and therapeutic strategies. The aim of this 
      study was to investigate the effect of treating breast CSCs with the anticancer 
      flavonoid, quercetin. MAIN METHODS: We examined changes in the cluster of 
      differentiation CD44(+)/CD24(-)CSC population and behavior using the breast 
      cancer cell line MCF-7. KEY FINDINGS: Our results indicated that cell viability, 
      clone formation, mammosphere generation, and nude mice tumor metastasis were 
      inhibited in the CD44(+)/CD24(-) population and that MCF-7 cells exhibited 
      G1-phase arrest after quercetin treatment. Additionally, CyclinD1 and B cell 
      lymphoma-2 expression were suppressed and Bcl-2-like protein-4 expression was 
      enhanced after quercetin treatment. We also observed that estrogen receptor alpha and 
      phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) 
      signaling were downregulated concurrently with the inhibition of CD44(+)/CD24(-) 
      viability and clone formation. Our findings suggested that quercetin treatment 
      promoted weaker malignant activity associated with CSCs relative to that observed 
      in normal cancer cells through its inhibition of the PI3K/Akt/mTOR-signaling 
      pathway. SIGNIFICANCE: These results indicated that CSCs are potential 
      therapeutic targets for quercetin treatment of breast cancer.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Li, Xiuli
AU  - Li X
AD  - Key Laboratory of Pharmacology, Chifeng University, Hongshan, Chifeng, Inner 
      Mongolia 024000, China.
FAU - Zhou, Na
AU  - Zhou N
AD  - Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao 
      266061, China.
FAU - Wang, Jin
AU  - Wang J
AD  - Affiliated People's Hospital of Inner Mongolia Medical University, Hohhot, Inner 
      Mongolia 010020, China.
FAU - Liu, Zhijie
AU  - Liu Z
AD  - Medical College of Chifeng University, Hongshan, Chifeng, Inner Mongolia 024000, 
      China.
FAU - Wang, Xiaohui
AU  - Wang X
AD  - Affiliated Hospital of Chifeng University, Hongshan, Chifeng, Inner Mongolia 
      024000, China.
FAU - Zhang, Qin
AU  - Zhang Q
AD  - Affiliated Hospital of Chifeng University, Hongshan, Chifeng, Inner Mongolia 
      024000, China.
FAU - Liu, Qingyan
AU  - Liu Q
AD  - Medical College of Chifeng University, Hongshan, Chifeng, Inner Mongolia 024000, 
      China.
FAU - Gao, Lifeng
AU  - Gao L
AD  - Medical College of Chifeng University, Hongshan, Chifeng, Inner Mongolia 024000, 
      China.
FAU - Wang, Rong
AU  - Wang R
AD  - Key Laboratory of Tropical Biological Resources of Ministry of Education, Hainan 
      University, Haikou, Hainan 570228, China; Department of Pharmacy, College of 
      Marine Science, Hainan University, Haikou, Hainan 570228, China. Electronic 
      address: wang832820@126.com.
LA  - eng
PT  - Journal Article
DEP - 20180121
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Antioxidants)
RN  - 0 (CD24 Antigen)
RN  - 0 (CD44 protein, human)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 9IKM0I5T1E (Quercetin)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Oncogene Protein v-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Antioxidants/*pharmacology
MH  - Apoptosis/drug effects
MH  - CD24 Antigen/*drug effects
MH  - Female
MH  - G1 Phase/drug effects
MH  - Humans
MH  - Hyaluronan Receptors/*drug effects
MH  - MCF-7 Cells
MH  - Mice, Nude
MH  - Oncogene Protein v-akt/*antagonists & inhibitors
MH  - *Phosphoinositide-3 Kinase Inhibitors
MH  - Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors
MH  - Quercetin/*pharmacology
MH  - Signal Transduction/*drug effects
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - Breast cancer
OT  - Cancer stem cells
OT  - Quercetin
EDAT- 2018/01/23 06:00
MHDA- 2018/02/27 06:00
CRDT- 2018/01/23 06:00
PHST- 2017/11/21 00:00 [received]
PHST- 2018/01/05 00:00 [revised]
PHST- 2018/01/13 00:00 [accepted]
PHST- 2018/01/23 06:00 [pubmed]
PHST- 2018/02/27 06:00 [medline]
PHST- 2018/01/23 06:00 [entrez]
AID - S0024-3205(18)30020-1 [pii]
AID - 10.1016/j.lfs.2018.01.014 [doi]
PST - ppublish
SO  - Life Sci. 2018 Mar 1;196:56-62. doi: 10.1016/j.lfs.2018.01.014. Epub 2018 Jan 21.